Introduction. Airway papillomatosis is caused by the human papillomavirus (HPV), of which subtypes 6 and 11 account for the highest rates of disease. Airway papillomatosis is characterized by the proliferation of benign squamous papillae in the respiratory tract. Papillomas can develop at any site in the airway but are most common in the larynx and vocal cords, with rare diffuse involvement in the lungs. Material and methods. The purpose of this study was to evaluate the different surgical and adjuvant therapies available for the treatment of this condition reported between 2019-2022. Results. A literature review was conducted through surveys based on electronic data in public areas such as PubMed. Thirty seven articles involving 1120 patients with laryngeal papillomatosis met the criteria. Of these, 22 articles research the use of adjuvant therapies and 15 surgical treatment. In the literature there has been an increase in the options of adjuvant therapy for PL in recent years. Treatment with bevacizumab and cidofovir can increase the interval between surgical procedures and decrease the number of procedures per year. Conclusions. Adjuvant therapies may be a viable option for prolonging the duration of RRP remission and improving the quality of life of patients and their families. However, more research is needed to assess effectiveness and adverse effects in different populations.